Cleavage of Syndecan-1 Promotes the Proliferation of the Basal-Like Breast Cancer Cell Line BT-549 Via Akt SUMOylation.

Satomi Nadanaka,Yaqiang Bai,Hiroshi Kitagawa

doi:10.3389/fcell.2021.659428

Abstract

Basal-like breast cancer is characterized by an aggressive clinical outcome and presence of metastasis, for which effective therapies are unavailable. We have previously shown that chondroitin 4-O-sulfotransferase-1 (C4ST-1) controls the invasive properties of the basal-like breast cancer cell line BT-549 by inducing matrix metalloproteinase (MMP) expression through the N-cadherin/β-catenin pathway. Here we report that C4ST-1 controls the proliferation of BT-549 cells via the MMP-dependent cleavage of syndecan-1. Syndecan-1 is a membrane-bound proteoglycan associated with an aggressive phenotype and poor prognosis in breast cancer. In addition, the cleavage of syndecan-1 at a specific juxtamembrane cleavage site is implicated in the pathophysiological response in breast cancer. Knockout of C4ST-1 remarkably suppressed both the cleavage of syndecan-1 and proliferation of BT-549 cells. Kinases (AKT1, ERK1/2, PI3K, and STAT3) comprising cancer proliferative pathways are phosphorylated in C4ST-1 knockout cells at a level similar to that in parental BT-549 cells, whereas levels of phosphorylated S6 kinase and SUMOylated AKT (hyperactivated AKT observed in breast cancer) decreased in C4ST-1 knockout cells. An MMP inhibitor, GM6001, suppressed the small ubiquitin-like modifier (SUMO) modification of AKT, suggesting that cleavage of syndecan-1 by MMPs is involved in the SUMO modification of AKT. Forced expression of the cytoplasmic domain of syndecan-1, which is generated by MMP-dependent cleavage, increased the SUMO modification of AKT and global protein SUMOylation. Furthermore, syndecan-1 C-terminal domain-expressing BT-549 cells were more proliferative and sensitive to a potent SUMOylation inhibitor, tannic acid, compared with BT-549 cells transfected with an empty expression vector. These findings assign new functions to the C-terminal fragment of syndecan-1 generated by MMP-dependent proteolysis, thereby broadening our understanding of their physiological importance and implying that the therapeutic inhibition of syndecan-1 cleavage could affect the progression of basal-like breast cancer.

Highlights

Chondroitin sulfate (CS), a glycosaminoglycan (GAG), is present on the cell surface and in the extracellular matrix (Sugahara et al, 2003)
We investigated whether matrix metalloproteinase (MMP) are involved in the proliferation of BT-549 cells (Figure 1G) because the loss of chondroitin 4-O-sulfotransferase-1 (C4ST-1) expression decreases the expression of matrix metalloproteinase 9 (MMP9), which is a target gene of β-catenin (Nadanaka et al, 2018)
We previously showed that CS produced by C4ST-1 induces the expression of MMP9 mediated via the N-cadherin/β-catenin pathway and upregulates the invasive activity of BT-549 cells

Summary

Introduction

Chondroitin sulfate (CS), a glycosaminoglycan (GAG), is present on the cell surface and in the extracellular matrix (Sugahara et al, 2003). There is ample evidence for the pro-tumorigenic role of CS in the enhancement of cell proliferation, cell motility, and metastasis. CS is a linear sulfated polymer consisting of repeating disaccharide units of glucuronic acid (GlcUA) and N-acetylgalactosamine (GalNAc) [-GlcUA-GalNAc-]n. During the synthesis of the CS backbone, various sulfotransferases catalyze sulfation. Chondroitin-4-O-sulfotransferase (C4ST-1) is involved in the biosynthesis of A-units [GlcUA-GalNAc(4O-sulfate)] and E-disaccharide units [GlcUA-GalNAc(4,6-Odisulfates)] (Nadanaka et al, 2008; Mikami and Kitagawa, 2013; Nadanaka et al, 2020). Specific sulfation patterns are believed to underlie the distinct functional roles of CS under physiological conditions and in tumor development and progression (Nadanaka et al, 2018)

Methods

Results

Conclusion